Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: A natural approach to complement pharmacotherapy in the management of diabetes

Molecular Nutrition and Food Research

Volumn 58, Issue 1, 2014, Pages 61-78

  Lacroix, Isabelle M E ^a   Li Chan, Eunice C Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antidiabetic medications; Complementary approaches; Diabetes; Dietary constituents; Glycemic regulation

Indexed keywords

ANTIDIABETIC AGENT;

ANTIDIABETIC MEDICATIONS; COMPLEMENTARY APPROACHES; DIABETES MELLITUS; DIET; DIET THERAPY; DIETARY CONSTITUENTS; FOOD ANALYSIS; GLYCEMIC REGULATION; HUMAN; REVIEW;

ANTIDIABETIC MEDICATIONS; COMPLEMENTARY APPROACHES; DIABETES; DIETARY CONSTITUENTS; GLYCEMIC REGULATION;

DIABETES MELLITUS; DIET; FOOD ANALYSIS; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84891428257     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300223     Document Type: Review

References (185)

1. Kim, J.-A., Hyun, T. K., Kim, M.-J., The inhibitory effects of ethanol extracts from sorghum, foxtail millet and proso millet on α-glucosidase and α-amylase activities. Food Chem. 2011, 124, 1647-1651.
2. Shaw, J. E., Sicree, R. A., Zimmet, P. Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 2010, 87, 4-14.
3. Schmidt, S. L., Hickey, M. S., Regulation of insulin action by diet and exercise. J. Equine Vet. Sci. 2009, 29, 274-284.
4. Fowler, M. J., Microvascular and macrovascular complications of diabetes. Clin. Diabetes 2008, 26, 77-82.
5. Blonde, L., Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus. Cleve. Clin. J. Med. 2009, 76 (Suppl 5), S4-S11.
6. Distefano, J. K., Watanabe, R. M., Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals (Basel) 2010, 3, 2610-2646.
7. Tahrani, A. A., Bailey, C. J., Del Prato, S., Barnett, A. H., Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378, 182-197.
8. Bennett, W. L., Wilson, L. M., Bolen, S., Maruthur, N. et al., Oral diabetes medications for adults with type 2 diabetes: an update [internet]. Comparative Effectiveness Review 2011, 27, Available from: http://www.ncbi.nlm.nih.gov/books/NBK55754/
9. Cheng, A. Y., Fantus, I. G., Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can. Med. Assoc. J. 2005, 172, 213-226.
10. Aggarwal, N., Shishu, A review of recent investigations on medicinal herbs possessing anti-diabetic properties. J. Nutrition. Disord. Ther. 2011, 1, 102. doi:10.4172/jndt.1000102.
11. Marles, R. J., Farnsworth, N. R., Antidiabetic plants and their active constituents. Phytomedicine 1995, 2, 137-189.
12. Robertson, M. D., Dietary-resistant starch and glucose metabolism. Curr. Opin. Clin. Nutr. Metab. Care. 2012, 15, 362-367.
13. Kaushik, G., Singhal, P., Prabhu, V. G., Antidiabetic potential of commonly consumed cereals - a review. J. Clin. Metab. & Diabetes 2011, 2, 68-74.
14. Åkerblom, H. K., Vaarala, O., Hyoty, H., Ilonen, J. et al., Environmental factors in the etiology of type 1 diabetes. Am. J. Med. Genet. 2002, 115, 18-29.
15. Merriman, T. R., Type 1 diabetes, the A1 milk hypothesis and vitamin D deficiency. Diabetes Res. Clin. Pract. 2009, 83, 149-156.
16. DeFronzo, R. A., Tripathy, D., Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32 (Suppl 2), S157-S163.
17. Defronzo, R. A., Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58, 773-795.
18. Landgraf, R., Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000, 17, 411-425.
19. Stumvoll, M., Goldstein, B. J., van Haeften, T. W., Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005, 365, 1333-1346.
20. Hatorp, V., Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet. 2002, 41, 471-483.
21. McLeod, J. F., Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clin. Pharmacokinet. 2004, 43, 97-120.
22. Lebovitz, H. E., Oral therapies for diabetic hyperglycemia. Endocrinol. Metab. Clin. North Am. 2001, 30, 909-933.
23. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012, 35 (Suppl 1), S11-S63.
24. Kim, Y. D., Park, K.-G., Lee, Y.-S., Park, Y.-Y. et al., Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008, 57, 306-314.
25. Kirpichnikov, D., McFarlane, S. I., Sowers, J. R., Metformin: an update. Ann. Intern. Med. 2002, 137, 25-33.
26. Marchetti, P., Lupi, R., Del Guerra, S., Bugliani, M. et al., Goals of treatment for type 2 diabetes: beta-cell preservation for glycemic control. Diabetes Care 2009, 32 (Suppl 2), S178-S183.
27. Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G. et al., Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001, 24, 489-494.
28. Yki-Järvinen, H., Thiazolidinediones. N. Engl. J. Med. 2004, 351, 1106-1118.
29. Ye, J. M., Dzamko, N., Cleasby, M. E., Hegarty, B. D. et al., Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 2004, 47, 1306-1313.
30. Lebovitz, H. E., Alpha-glucosidase inhibitors. Endocrinol. Metab. Clin. North Am. 1997, 26, 539-551.
31. Addison, D., Aguilar, D., Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies. Curr. Atheroscler. Rep. 2011, 13, 115-122.
32. Holst, J. J., Deacon, C. F., Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol. 2004, 4, 589-596.
33. Mentlein, R., Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs. Expert Opin. Investig. Drugs 2005, 14, 57-64.
34. Holst, J. J., Gromada, J., Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol. Endocrinol. Metab. 2004, 287, E199-E206.
35. Stoffers, D. A., Desai, B. M., DeLeon, D. D., Simmons, R. A., Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. Diabetes 2003, 52, 734-740.
36. Wajchenberg, B. L., β-Cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 2007, 28, 187-218.
37. Lambeir, A.-M., Durinx, C., Scharpé, S., De Meester, I., Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 2003, 40, 209-294.
38. Lorey, S., Stöckel-Maschek, A., Faust, J., Brandt, W. et al., Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites. Eur. J. Biochem. 2003, 270, 2147-2156.
39. Thoma, R., Löffler, B., Stihle, M., Huber, W. et al., Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure 2003, 11, 947-959.
40. Adeghate, E., Kalász, H., Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med. Chem. J. 2011, 5, 78-81.
41. Schmitz, O., Brock, B., Rungby, J., Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004, 53 (Suppl 3), S233-S238.
42. Michel, S., Becskei, C., Erguven, E., Lutz, T. A. et al., Diet-derived nutrients modulate the effects of amylin on c-Fos expression in the area postrema and on food intake. Neuroendocrinology 2007, 86, 124-135.
43. Young, A., Inhibition of food intake. Adv. Pharmacol. 2005, 52, 79-98.
44. Keche, Y., Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control. J. Pharm. Bioallied Sci. 2010, 2, 148-150.
45. Shivaprasad, C., Kalra, S., Bromocriptine in type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2011, 15, S17-S24.
46. Defronzo, R. A., Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care 2011, 34, 789-794.
47. Sonnett, T. E., Levien, T. L., Neumiller, J. J., Gates, B. J. et al., Colesevelam hydrochloride for the treatment of type 2 diabetes mellitus. Clin. Ther. 2009, 31, 245-259.
48. Handelsman, Y., Role of bile acid sequestrants in the treatment of type 2 diabetes. Diabetes Care 2011, 34 (Suppl 2), S244-S250.
49. Lefebvre, P., Cariou, B., Lien, F., Kuipers, F. et al., Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89, 147-191.
50. Zhang, Y., Lee, F. Y., Barrera, G., Lee, H. et al., Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA 2006, 103, 1006-1011.
51. Ma, K., Saha, P. K., Chan, L., Moore, D. D., Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 2006, 116, 1102-1109.
52. Suzuki, T., Oba, K., Igari, Y., Matsumura, N. et al., Colestimide lowers plasma glucose levels and increases plasma glucagon-like peptide-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J. Nippon Med. Sch. 2007, 74, 338-343.
53. Beysen, C., Murphy, E. J., Deines, K., Chan, M. et al., Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study. Diabetologia 2012, 55, 432-442.
54. Feskens, E. J., Virtanen, S. M., Räsänen, L., Tuomilehto, J. et al., Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995, 18, 1104-1112.
55. Ford, E. S., Mokdad, A. H., Fruit and vegetable consumption and diabetes mellitus incidence among U.S. adults. Prev. Med. 2001, 32, 33-39.
56. Montonen, J., Järvinen, R., Heliövaara, M., Reunanen, A. et al., Food consumption and the incidence of type II diabetes mellitus. Eur. J. Clin. Nutr. 2005, 59, 441-448.
57. Montonen, J., Knekt, P., Järvinen, R., Aromaa, A. et al., Whole-grain and fiber intake and the incidence of type 2 diabetes. Am. J. Clin. Nutr. 2003, 77, 622-629.
58. Liu, S., Manson, J. E., Stampfer, M. J., Hu, F. B. et al., A prospective study of whole-grain intake and risk of type 2 diabetes mellitus in US women. Am. J. Public Health 2000, 90, 1409-1415.
59. Fung, T. T., Hu, F. B., Pereira, M. A., Liu, S. et al., Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Am. J. Clin. Nutr. 2002, 76, 535-540.
60. de Munter, J. S., Hu, F. B., Spiegelman, D., Franz, M. et al., Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review. PLoS Med. 2007, 4, e261.
61. Fretts, A. M., Howard, B. V., McKnight, B., Duncan, G. E. et al., Associations of processed meat and unprocessed red meat intake with incident diabetes: the Strong Heart Family Study. Am. J. Clin. Nutr. 2012, 95, 752-758.
62. van Dam, R. M., Willett, W. C., Rimm, E. B., Stampfer, M. J. et al., Dietary fat and meat intake in relation to risk of type 2 diabetes in men. Diabetes Care 2002, 25, 417-424.
63. Schulze, M. B., Manson, J. E., Willett, W. C., Hu, F. B., Processed meat intake and incidence of type 2 diabetes in younger and middle-aged women. Diabetologia 2003, 46, 1465-1473.
64. McDougall, G. J., Shpiro, F., Dobson, P., Smith, P. et al., Different polyphenolic components of soft fruits inhibit α-amylase and α-glucosidase. J. Agric. Food Chem. 2005, 53, 2760-2766.
65. McCue, P., Kwon, Y.-I., Shetty, K., Anti-amylase and anti-angiotensin I-converting enzyme potential of selected foods. J. Food Biochem. 2005, 29, 278-294.
66. De Souza Schmidt Gonçalves, A. E., Lajolo, F. M., Genovese, M. I., Chemical composition and antioxidant/antidiabetic potential of Brazilian native fruits and commercial frozen pulps. J. Agric. Food Chem. 2010, 58, 4666-4674.
67. da Silva Pinto, M., Kwon, Y.-I., Apostolidis, E., Lajolo, F. M. et al., Functionality of bioactive compounds in Brazilian strawberry (Fragaria x ananassa Duch.) cultivars: evaluation of hyperglycemia and hypertension potential using in vitro models. J. Agric. Food Chem 2008, 56, 4386-4392.
68. Oboh, G., Akinyemi, A. J., Ademiluyi, A. O., Adefegha, S. A., Inhibitory effects of aqueous extract of two varieties of ginger on some key enzymes linked to type-2 diabetes in vitro. J. Food Nutr. Res. 2010, 49, 14-20.
69. Etxeberria, U., de la Garza, A. L., Campión, J., Martinez, J. A. et al., Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase. Expert Opin. Ther. Targets 2012, 16, 269-297.
70. You, Q., Chen, F., Wang, X., Jiang, Y. et al., Anti-diabetic activities of phenolic compounds in muscadine against alpha-glucosidase and pancreatic lipase. LWT - Food Sci. Technol. 2012, 46, 164-168.
71. Shobana, S., Sreerama, Y. N., Malleshi, N. G., Composition and enzyme inhibitory properties of finger millet (Eleusine coracana L.) seed coat phenolics: mode of inhibition of α-glucosidase and pancreatic amylase. Food Chem. 2009, 115, 1268-1273.
72. Tadera, K., Minami, Y., Takamatsu, K., Matsuoka, T., Inhibition of α-glucosidase and α-amylase by flavonoids. J. Nutr. Sci. Vitaminol. (Tokyo) 2006, 52, 149-153.
73. Kim, J.-S., Kwon, C.-S., Son, K. H., Inhibition of alpha-glucosidase and amylase by luteolin, a flavonoid. Biosci. Biotechnol. Biochem. 2000, 64, 2458-2461.
74. Matsui, T., Kobayashi, M., Hayashida, S., Matsumoto, K., Luteolin, a flavone, does not suppress postprandial glucose absorption through an inhibition of a-glucosidase action. Biosci. Biotechnol. Biochem. 2002, 66, 689-692.
75. Serrano, J., Puupponen-Pimiä, R., Dauer, A., Aura, A.-M. et al., Tannins: current knowledge of food sources, intake, bioavailability and biological effects. Mol. Nutr. Food Res. 2009, 53 (Suppl 2), S310-S329.
76. Gonçalves, R., Mateus, N., de Freitas, V., Inhibition of α-amylase activity by condensed tannins. Food Chem. 2011, 125, 665-672.
77. Matsui, T., Yoshimoto, C., Osajima, K., Oki, T. et al., In vitro survey of α-glucosidase inhibitory food components. Biosci. Biotechnol. Biochem. 1996, 60, 2019-2022.
78. Yu, Z., Yin, Y., Zhao, W., Yu, Y. et al., Novel peptides derived from egg white protein inhibiting alpha-glucosidase. Food Chem. 2011, 129, 1376-1382.
79. Shimizu, M., Kobayashi, Y., Suzuki, M., Satsu, H. et al., Regulation of intestinal glucose transport by tea catechins. Biofactors 2000, 13, 61-65.
80. Manzano, S., Williamson, G., Polyphenols and phenolic acids from strawberry and apple decrease glucose uptake and transport by human intestinal Caco-2 cells. Mol. Nutr. Food Res. 2010, 54, 1773-1780.
81. Kobayashi, Y., Suzuki, M., Satsu, H., Arai, S. et al., Green tea polyphenols inhibit the sodium-dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. J. Agric. Food Chem. 2000, 48, 5618-5623.
82. Kwon, O., Eck, P., Chen, S., Corpe, C. P. et al., Inhibition of the intestinal glucose transporter GLUT2 by flavonoids. FASEB J. 2007, 21, 366-377.
83. Johnston, K., Sharp, P., Clifford, M., Morgan, L., Dietary polyphenols decrease glucose uptake by human intestinal Caco-2 cells. FEBS Lett. 2005, 579, 1653-1657.
84. Agius, L., New hepatic targets for glycaemic control in diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 2007, 21, 587-605.
85. Nordlie, R. C., Foster, J. D., Lange, A. J., Regulation of glucose production by the liver. Annu. Rev. Nutr. 1999, 19, 379-406.
86. Bandsma, R. H., Wiegman, C. H., Herling, A. W., Burger, H.-J. et al., Acute inhibition of glucose-6-phosphate translocator activity leads to increased de novo lipogenesis and development of hepatic steatosis without affecting VLDL production in rats. Diabetes 2001, 50, 2591-2597.
87. Arion, W. J., Canfield, W. K., Ramos, F. C., Schindler, P. W. et al., Chlorogenic acid and hydroxynitrobenzaldehyde: new inhibitors of hepatic glucose 6-phosphatase. Arch. Biochem. Biophys. 1997, 339, 315-322.
88. Charkoudian, L. K., Farrell, B. P., Khosla, C., Natural product inhibitors of glucose-6-phosphate translocase. Med. Chem. Commun. 2012, 3, 926-931.
89. Henry-Vitrac, C., Ibarra, A., Roller, M., Mérillon, J.-M. et al., Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract. J. Agric. Food Chem. 2010, 58, 4141-4144.
90. Salazar-Martinez, E., Willett, W. C., Ascherio, A., Manson, J. E. et al., Coffee consumption and risk for type 2 diabetes mellitus. Ann. Intern. Med. 2004, 140, 1-8.
91. van Dam, R. M., Feskens, E. J., Coffee consumption and risk of type 2 diabetes mellitus. Lancet 2002, 360, 1477-1478.
92. Huxley, R., Lee, C. M., Barzi, F., Timmermeister, L. et al., Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch. Intern. Med. 2009, 169, 2053-2063.
93. Jenkins, D. J., Wolever, T. M., Leeds, A. R., Gassull, M. A. et al., Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity. Br. Med. J. 1978, 1, 1392-1394.
94. Braaten, J. T., Wood, P. J., Scott, F. W., Riedel, K. D. et al., Oat gum lowers glucose and insulin after an oral glucose load. Am. J. Clin. Nutr. 1991, 53, 1425-1430.
95. Granfeldt, Y., Hagander, B., Bjorck, I., Metabolic responses to starch in oat and wheat products. On the importance of food structure, incomplete gelatinization or presence of viscous dietary fibre. Eur. J. Clin. Nutr. 1995, 49, 189-199.
96. Hallfrisch, J., Scholfield, D. J., Behall, K. M., Diets containing soluble oat extracts improve glucose and insulin responses of moderately hypercholesterolemic men and women. Am. J. Clin. Nutr. 1995, 61, 379-384.
97. Wolever, T. M., Bolognesi, C., Source and amount of carbohydrate affect postprandial glucose and insulin in normal subjects. J. Nutr. 1996, 126, 2798-2806.
98. Yokoyama, W. H., Hudson, C. A., Knuckles, B., Chui, M.-C. M. et al., Effect of barley beta-glucan in durum wheat pasta on human glycemic response. Cereal Chem. 1997, 74, 293-296.
99. Urooj, A., Vinutha, S. R., Puttaraj, S., Leelavathy, K. et al., Effect of barley incorporation in bread on its quality and glycemic responses in diabetics. Int. J. Food Sci. Nutr. 1998, 49, 265-270.
100. Vuorinen-Markkola, H., Sinisalo, M., Koivisto, V. A., Guar gum in insulin-dependent diabetes: effects on glycemic control and serum lipoproteins. Am. J. Clin. Nutr. 1992, 56, 1056-1060.
101. Torsdottir, I., Alpsten, M., Andersson, H., Einarsson, S., Dietary guar gum effects on postprandial blood glucose, insulin and hydroxyproline in humans. J. Nutr. 1989, 119, 1925-1931.
102. Maki, K. C., Carson, M. L., Miller, M. P., Turowski, M. et al., High-viscosity hydroxypropylmethylcellulose blunts postprandial glucose and insulin responses. Diabetes Care 2007, 30, 1039-1043.
103. Srinivasan, K., Plant foods in the management of diabetes mellitus: spices as beneficial antidiabetic food adjuncts. Int. J. Food Sci. Nutr. 2005, 56, 399-414.
104. Benini, L., Castellani, G., Brighenti, F., Heaton, K. W. et al., Gastric emptying of a solid meal is accelerated by the removal of dietary fibre naturally present in food. Gut 1995, 36, 825-830.
105. Edwards, C. A., Johnson, I. T., Read, N. W., Do viscous polysaccharides slow absorption by inhibiting diffusion or convection? Eur. J. Clin. Nutr. 1988, 42, 307-312.
106. Lavin, J. H., Read, N. W., The effect on hunger and satiety of slowing the absorption of glucose: relationship with gastric emptying and postprandial blood glucose and insulin responses. Appetite 1995, 25, 89-96.
107. Kim, W., Egan, J. M., The role of incretins in glucose homeo-stasis and diabetes treatment. Pharmacol. Rev. 2008, 60, 470-512.
108. Murphy, M. M., Douglass, J. S., Birkett, A., Resistant starch intakes in the United States. J. Am. Diet. Assoc. 2008, 108, 67-78.
109. Zhou, J., Hegsted, M., McCutcheon, K. L., Keenan, M. J. et al., Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. Obesity (Silver Spring) 2006, 14, 683-689.
110. Zhou, J., Martin, R. J., Tulley, R. T., Raggio, A. M. et al., Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E1160-E1166.
111. Keenan, M. J., Zhou, J., McCutcheon, K. L., Raggio, A. M. et al., Effects of resistant starch, a non-digestible fermentable fiber, on reducing body fat. Obesity (Silver Spring) 2006, 14, 1523-1534.
112. Gee, J. M., Johnson, I. T., Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. Nutrition 2005, 21, 1036-1043.
113. Greenway, F., O'Neil, C. E., Stewart, L., Rood, J. et al., Fourteen weeks of treatment with Viscofiber® increased fasting levels of glucagon-like peptide-1 and peptide-YY. J. Med. Food 2007, 10, 720-724.
114. Freeland, K. R., Wilson, C., Wolever, T. M. S., Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. Br. J. Nutr. 2010, 103, 82-90.
115. Reimer, R. A., Meat hydrolysate and essential amino acid-induced glucagon-like peptide-1 secretion, in the human NCI-H716 enteroendocrine cell line, is regulated by extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinases. J. Endocrinol. 2006, 191, 159-170.
116. Hall, W. L., Millward, D. J., Long, S. J., Morgan, L. M., Casein and whey exert different effects on plasma amino acid profiles, gastrointestinal hormone secretion and appetite. Br. J. Nutr. 2003, 89, 239-248.
117. Chen, Q., Reimer, R. A., Dairy protein and leucine alter GLP-1 release and mRNA of genes involved in intestinal lipid metabolism in vitro. Nutrition 2009, 25, 340-349.
118. Mochida, T., Hira, T., Hara, H., The corn protein, zein hydrolysate, administered into the ileum attenuates hyperglycemia via its dual action on glucagon-like peptide-1 secretion and dipeptidyl peptidase-IV activity in rats. Endocrinology 2010, 151, 3095-3104.
119. Tulipano, G., Sibilia, V., Caroli, A. M., Cocchi, D., Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors. Peptides 2011, 32, 835-838.
120. Tulipano, G., Cocchi, D., Caroli, A. M., Comparison of goat and sheep β-lactoglobulin to bovine β-lactoglobulin as potential source of dipeptidyl peptidase IV (DPP-4) inhibitors. Int. Dairy J. 2012, 24, 97-101.
121. Uchida, M., Ohshiba, Y., Mogami, O., Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin. J. Pharmacol. Sci. 2011, 117, 63-66.
122. Uenishi, H., Kabuki, T., Seto, Y., Serizawa, A. et al., Isolation and identification of casein-derived dipeptidyl-peptidase 4 (DPP-4)-inhibitory peptide LPQNIPPL from gouda-type cheese and its effect on plasma glucose in rats. Int. Dairy J. 2012, 22, 24-30.
123. Lacroix, I. M. E., Li-Chan, E. C. Y., Dipeptidyl peptidase-IV inhibitory activity of dairy protein hydrolysates. Int. Dairy J. 2012, 25, 97-102.
124. Van Amerongen, A., Beelen-Thomissen, M. J. C., Van Zeeland-Wolbers, L. A. M., Van Gilst, W. H. et al., Egg protein hydrolysates. Int. Pat. No. WO 2009/128713 A1.
125. Hatanaka, T., Inoue, Y., Arima, J., Kumagai, Y. et al., Production of dipeptidyl peptidase IV inhibitory peptides from defatted rice bran. Food Chem. 2012, 134, 797-802.
126. Li-Chan, E. C.Y, Hunag, S.-L., Jao, C.-L., Ho, K.-P. et al., Peptides derived from Atlantic salmon skin gelatin as dipeptidyl-peptidase IV inhibitors. J. Agric. Food Chem. 2012, 60, 973-978.
127. Huang, S.-L., Jao, C.-L., Ho, K.-P., Hsu, K.-C., Dipeptidyl-peptidase IV inhibitory activity of peptides derived from tuna cooking juice hydrolysates. Peptides 2012, 35, 114-121.
128. Kühn-Wache, K., Bär, J. W., Hoffmann, T., Wolf, R. et al., Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site. Biol. Chem. 2011, 392, 223-231.
129. Rahfeld, J., Schierhorn, M., Hartrodt, B., Neubert, K. et al., Are diprotin A (Ile-Pro-Ile) and diprotin B (Val-Pro-Leu) inhibitors or substrates of dipeptidyl peptidase IV? Biochim. Biophys. Acta 1991, 1076, 314-316.
130. Ma, J., Li, Z., Xing, S., Ho, W. T. et al., Tea contains potent inhibitors of tyrosine phosphatase PTP1B. Biochem. Biophys. Res. Commun. 2011, 407, 98-102.
131. Goldstein, B. J., Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J. Clin. Endocrinol. Metab. 2002, 87, 2474-2480.
132. Johnson, T. O., Ermolieff, J., Jirousek, M. R., Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat. Rev. Drug Discov. 2002, 1, 696-709.
133. Goldstein, B. J., Bittner-Kowalczyk, A., White, M. F., Harbeck, M., Tyrosine dephosphorylation and deactivation of insulin receptor substrate-1 by protein-tyrosine phosphatase 1B. Possible facilitation by the formation of a ternary complex with the Grb2 adaptor protein. J. Biol. Chem. 2000, 275, 4283-4289.
134. Lund, I. K., Hansen, J. A., Andersen, H. S., Møller, N. P. et al., Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling. J. Mol. Endocrinol. 2005, 34, 339-351.
135. Teng, B.-S., Wang, C.-D., Yang, H.-J., Wu, J.-S. et al., A protein tyrosine phosphatase 1B activity inhibitor from the fruiting bodies of Ganoderma lucidum (Fr.) karst and its hypoglycemic potency on streptozotocin-induced type 2 diabetic mice. J. Agric. Food Chem. 2011, 59, 6492-6500.
136. Imparl-Radosevich, J., Deas, S., Polansky, M. M., Baedke, D. A. et al., Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signalling. Horm. Res. 1998, 50, 177-182.
137. Khan, A., Bryden, N. A., Polansky, M. M., Anderson, R. A., Insulin potentiating factor and chromium content of selected foods and spices. Biol. Trace Elem. Res. 1990, 24, 183-188.
138. Penumetcha, M., Santanam, N., Nutraceuticals as ligands of PPAR-γ. PPAR Res. 2012, 2012, 858352.
139. Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20, 649-688.
140. Belury, M. A., Moya-Camarena, S. Y., Lu, M., Shi, L. et al., Conjugated linoleic acid is an activator and ligand for peroxisome proliferator-activated receptor-gamma (PPAR-γ). Nutr. Res. 2002, 22, 817-824.
141. Itoh, T., Fairall, L., Amin, K., Inaba, Y. et al., Structural basis for the activation of PPARγ by oxidized fatty acids. Nat. Struct. Mol. Biol. 2008, 15, 924-931.
142. Medjakovic, S., Mueller, M., Jungbauer, A., Potential health-modulating effects of isoflavones and metabolites via activation of PPAR and AhR. Nutrients 2010, 2, 241-279.
143. Dang, Z.-C., Audinot, V., Papapoulos, S. E., Boutin, J. A. et al., Peroxisome proliferator-activated receptor γ (PPARγ) as a molecular target for the soy phytoestrogen genistein. J. Biol. Chem. 2003, 278, 962-967.
144. Chacko, B. K., Chandler, R. T., D'Alessandro, T. L., Mundhekar, A. et al., Anti-inflammatory effects of isoflavones are dependent on flow and human endothelial cell PPARγ. J. Nutr. 2007, 137, 351-356.
145. Cho, K. W., Lee, O.-H., Banz, W. J., Moustaid-Moussa, N. et al., Daidzein and the daidzein metabolite, equol, enhance adipocyte differentiation and PPARγ transcriptional activity. J. Nutr. Biochem. 2010, 21, 841-847.
146. Christensen, K. B., Minet, A., Svenstrup, H., Grevsen, K. et al., Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake. Phytother. Res. 2009, 23, 1316-1325.
147. Rau, O., Wurglics, M., Paulke, A., Zitzkowski, J. et al., Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma. Planta Med. 2006, 72, 881-887.
148. Jungbauer, A., Medjakovic, S., Anti-inflammatory properties of culinary herbs and spices that ameliorate the effects of metabolic syndrome. Maturitas 2012, 71, 227-239.
149. Han, K. L., Jung, M. H., Sohn, J. H., Hwang, J.-K., Ginsenoside 20(S)-protopanaxatriol (PPT) activates peroxisome proliferator-activated receptor γ (PPARγ) in 3T3-L1 adipocytes. Biol. Pharm. Bull. 2006, 29, 110-113.
150. Salam, N. K., Huang, T.H-W., Kota, B. P., Kim, M. S. et al., Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. Chem. Biol. Drug Des. 2008, 71, 57-70.
151. Liang, Y.-C., Tsai, S.-H., Tsai, D.-C., Lin-Shiau, S.-Y. et al., Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-γ by flavonoids in mouse macrophages. FEBS Lett. 2001, 496, 12-18.
152. Zhang, B., Salituro, G., Szalkowski, D., Li, Z. et al., Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284, 974-977.
153. Tsai, H. J., Chou, S.-Y., A novel hydroxyfuroic acid compound as an insulin receptor activator. Structure and activity relationship of a prenylindole moiety to insulin receptor activation. J. Biomed. Sci. 2009, 16, 68. doi:10.1186/1423-0127-16-68.
154. García-Vicente, S., Yraola, F., Marti, L., González-Muñoz, E. et al., Oral insulin-mimetic compounds that act independently of insulin. Diabetes 2007, 56, 486-493.
155. He, K., Chan, C.-B., Liu, X., Jia, Y. et al., Identification of a molecular activator for insulin receptor with potent anti-diabetic effects. J. Biol. Chem. 2011, 286, 37379-37388.
156. Broadhurst, C. L., Polansky, M. M., Anderson, R. A., Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro. J. Agric. Food Chem. 2000, 48, 849-852.
157. Anderson, R. A., Polansky, M. M., Tea enhances insulin activity. J. Agric. Food Chem. 2002, 50, 7182-7186.
158. Anderson, R. A., Broadhurst, C. L., Polansky, M. M., Schmidt, W. F. et al., Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. J. Agric. Food Chem. 2004, 52, 65-70.
159. Bertoglio, J. C., Calvo, M. A., Hancke, J. L., Burgos, R. A. et al., Hypoglycemic effect of lupin seed γ-conglutin in experimental animals and healthy human subjects. Fitoterapia 2011, 82, 933-938.
160. Terruzzi, I., Senesi, P., Magni, C., Montesano, A. et al., Insulin-mimetic action of conglutin-γ, a lupin seed protein, in mouse myoblasts. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 197-205.
161. Scarafoni, A., Magni, C., Duranti, M., Molecular nutraceutics as a mean to investigate the positive effects of legume seed proteins on human health. Trends Food Sci. Technol. 2007, 18, 454-463.
162. Liu, X., Kim, J.-K., Li, Y., Li, J. et al., Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells. J. Nutr. 2005, 135, 165-171.
163. Li, Y., Kim, J., Li, J., Liu, F. et al., Natural anti-diabetic compound 1, 2, 3, 4, 6-penta-O-galloyl-d-glucopyranose binds to insulin receptor and activates insulin-mediated glucose transport signaling pathway. Biochem. Biophys. Res. Commun. 2005, 336, 430-437.
164. Liu, C.-T., Sheen, L.-Y., Lii, C.-K., Does garlic have a role as an antidiabetic agent? Mol. Nutr. Food Res. 2007, 51, 1353-1364.
165. Hanhineva, K., Törrönen, R., Bondia-Pons, I., Pekkinen, J. et al., Impact of dietary polyphenols on carbohydrate metabolism. Int. J. Mol. Sci. 2010, 11, 1365-1402.
166. Jayaprakasam, B., Vareed, S. K., Olson, L. K., Nair, M. G., Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits. J. Agric. Food Chem. 2005, 53, 28-31.
167. Liu, C. T., Hse, H., Lii, C. K., Chen, P. S. et al., Effects of garlic oil and diallyl trisulfide on glycemic control in diabetic rats. Eur. J. Pharmacol. 2005, 516, 165-173.
168. Augusti, K. T., Sheela, C. G., Antiperoxide effect of S-allyl cysteine sulfoxide, an insulin secretagogue, in diabetic rats. Experientia 1996, 52, 115-120.
169. Yibchok-anun, S., Adisakwattana, S., Yao, C. Y., Sangvanich, P. et al., Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol. Pharm. Bull. 2006, 29, 1126-1131.
170. Rösen, P., Nawroth, P. P., King, G., Möller, W. et al., The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev. 2001, 17, 189-212.
171. Chang, Y.-C., Chuang, L.-M., The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Am. J. Transl. Res. 2010, 2, 316-331.
172. Henriksen, E. J., in: Watson, R. R., Preedy, V. R. (Eds.), Bioactive Food as Dietary Interventions for Diabetes, Academic Press, San Diego 2013, pp. 1-15.
173. Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 2010, 107, 1058-1070.
174. Dembinska-Kiec, A., Mykkänen, O., Kiec-Wilk, B., Mykkänen, H., Antioxidant phytochemicals against type 2 diabetes. Br. J. Nutr. 2008, 99, ES109-ES117.
175. Johansen, J. S., Harris, A. K., Rychly, D. J., Ergul, A., Oxidative stress and the use of antioxidants in diabetes: linking basic science to clinical practice. Cardiovasc. Diabetol. 2005, 4, 5.
176. Yu, Z.-W., Li, D., Ling, W.-H., Jin, T.-R., Role of nuclear factor (erythroid-derived 2)-like 2 in metabolic homeostasis and insulin action: a novel opportunity for diabetes treatment? World J. Diabetes 2012, 3, 19-28.
177. Qin, S, Chen, J., Tanigawa, S., Hou, D.-X., Microarray and pathway analysis highlight Nrf2/ARE-mediated expression profiling by polyphenolic myricetin. Mol. Nutr. Food Res. 2013, 57, 435-446.
178. Chartoumpekis, D. V., Kensler, T. W., New player on an old field; the Keap1/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome. Curr. Diabetes Rev. 2013, 9, 137-145.
179. Akash, M. S. H., Rehman, K., Chen, S., Role of inflammatory mechanisms in the pathogenesis of type 2 diabetes. J. Cell. Biochem. 2013, 114, 525-531.
180. Cao, G., Booth, S. L., Sadowski, J. A., Prior, R. L., Increases in human plasma antioxidant capacity after consumption of controlled diets high in fruit and vegetables. Am. J. Clin. Nutr. 1998, 68, 1081-1087.
181. Cao, G., Russell, R. M., Lischner, N., Prior, R. L., Serum antioxidant capacity is increased by consumption of strawberries, spinach, red wine or vitamin C in elderly women. J. Nutr. 1998, 128, 2383-2390.
182. Lean, M. E., Noroozi, M., Kelly, I., Burns, J. et al., Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA. Diabetes 1999, 48, 176-181.
183. Jacob, S., Ruus, P., Hermann, R., Tritschler, H. J. et al., Oral administration of RAC-α-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic. Biol. Med. 1999, 27, 309-314.
184. Ziegler, D., Nowak, H., Kempler, P., Vargha, P. et al., Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a meta-analysis. Diabet. Med. 2004, 21, 114-121.
185. Akbar, S., Bellary, S., Griffiths, H. R., Dietary antioxidant interventions in type 2 diabetes patients: a meta-analysis. Br. J. Diabetes Vas. Dis. 2011, 11, 62-68.